Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Invested Capital (2021 - 2025)

Arrowhead Pharmaceuticals' Return on Invested Capital history spans 5 years, with the latest figure at 0.48% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 552.0% year-over-year to 0.48%; the TTM value through Dec 2025 reached 0.48%, up 552.0%, while the annual FY2025 figure was 0.16%, 266.0% up from the prior year.
  • Return on Invested Capital reached 0.48% in Q4 2025 per ARWR's latest filing, up from 0.1% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.48% in Q4 2025 to a low of 5.04% in Q4 2024.
  • Average Return on Invested Capital over 5 years is 0.83%, with a median of 0.4% recorded in 2022.
  • Peak YoY movement for Return on Invested Capital: tumbled -374bps in 2024, then skyrocketed 552bps in 2025.
  • A 5-year view of Return on Invested Capital shows it stood at 0.48% in 2021, then rose by 18bps to 0.4% in 2022, then crashed by -228bps to 1.3% in 2023, then tumbled by -288bps to 5.04% in 2024, then surged by 109bps to 0.48% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Return on Invested Capital are 0.48% (Q4 2025), 0.1% (Q3 2025), and 0.17% (Q2 2025).